their ability to bind to the 3'-untranslated regions (UTRs) of messenger RNAs, where they interfere with translation, and thereby regulate cell differentiation, apoptosis, and tumorigenesis. Since their initial discovery in 1993 [1] , several published data found that some of these miRNAs act as oncogenes, whereas others exhibit tumor suppressor properties [2] [3] [4] . Altered miRNA expression has been implicated in several carcinomas, including non-small cell lung cancer (NSCLC); moreover, aberrant expression of miRNAs is significantly related to tumor stage, suggesting that they could be potential markers for cancer prognosis [5] [6] .
Similar to breast cancer, let-7 is down regulated in NSCLC [7] [8] [9] . Several investigators have shown that let-7 harbors tumor suppressive properties both in vitro and in vivo [10] [11] [12] [13] .
MiR-21 has been identified as the best hit in a number of high-through screen experiments designed for the detection of cancer related miRNAs [14] . The exact molecular mechanism of miR-21 elevation and its role in cancer development and progression is currently unclear. Interestingly, several miRNAs, including miR-205, seem to be differently involved in the pathogenesis of the two major NSCLC histologies, adenocarcinomas (ADCs) and squamous cell carcinomas (SCCs).
Moreover, recent published studies [15] [16] [17] [18] have correlated miRNA expression with prognosis in lung cancer, arising the possibility of using miRNA expression profiles to predict outcomes in NSCLC, especially in early stage lung cancer patients in order to identify those at high risk of relapse after surgical resection [19] .
The aim of this study was to evaluate let-7g, miR-21 and miR-205 expression in a series of 105 early-stage (T1N0) NSCLC patients to establish their potential prognostic value.
Patients and Methods

Patients Selection
One hundred and five NSCLC cases were retrospectively selected from patients operated at the Unit of Thoracic Surgery of the A.O.U.P. between 2000 and 2010. Histological diagnoses were independently formulated by two pathologists (G.F. and G.A.) according to the World Health Organization classification [20] [21] [22] . Clinico-pathological characteristics and clinical data were collected for all the patients. All the patients gave their informed consent to the molecular analyses.
RNA Isolation
Total RNA including miRNAs was isolated from 5 -10 μm sections of formalin-fixed and paraffin-embedded (FFPE) tissues after manual tumor macrodissection using the miRNeasy FFPE Kit (Qiagen), according to the manufacturer's instructions.
miRNA Expression
Quantification of let-7g, miR-21, miR-205, and RNU6B expression was carried out in triplicate into 105 NSCLC and into a pool of 27 non-cancerous lung tissues using specific TaqMan ® MicroRNA Assays (Applied Biosystems), according to the manufacturer's instructions. Briefly, 10 ng of RNA were retro-transcribed by the TaqMan ® MicroRNA Reverse Transcription (RT) Kit (Applied Biosystems), and 1.3 μl of RT product were analysed by quantitative Real Time-PCR (qRT-PCR) on the Rotor-Gene 6000 (Corbett Research).
Threshold cycle (Ct) and baselines were determined by manual settings. miRNA expression was calculated by relative quantification and fold expression changes were determined by the 2 −ΔΔCt method using the DataAssist TM software (Applied Biosystems).
Statistical Analysis
One-way analysis of variance and χ 2 test were used to determine the association between miRNA expression and the different parameters, while survival analysis was performed by the Kaplan-Meier method. Statistical analyses were performed using the JMP10 software (SAS) and a two-tailed p value <0.05 was considered significant.
Results
Patient Characteristics
This study was conducted in 105 patients with early-stage NSCLC (T1N0), including 57 adenocarcinomas (ADCs), and 48 squamous cell carcinomas (SCCs). As regards histological classification, different histologic subtypes of adenocarcinoma were recognised: acinar (20/57, 35%), lepidic (18/57, 31.6%), mucinous (9/57, 15.8%), papillar (7/57, 12.3%), and solid (3/57, 5.3%) variants.
The median age at diagnosis was 67 years (range: 49 -81) and the median follow up was 63 months (range: 6 -161). Regarding grading, 5 tumors were G1, whereas 73 and 27 were G2 and G3, respectively. Disease progression and death from lung cancer were observed in 27 (25.7%) and in 21 (20%) of the 105 NSCLC patients, respectively. The median progression-free survival (PFS) and overall survival (OS) were 58 months (95% CI: 6 -161) and 69 months (95% CI: 11 -161), respectively. Regarding smoking habits, there were 15 non-smokers, 45 former smokers, and 45 current smokers.
let-7g, miR-21, and miR-205 Expression Profile and Clinico-Pathological Characteristics
We quantified the mature let-7g, miR-21, and miR-205 expression normalized to the RNU6B endogenous control in 105 NSCLC and in non-cancerous tissues. To determine whether miRNA profile was correlated with the main clinico-pathological characteristics, the NSCLC patients were divided into let-7g, miR-21, and miR-205 high and low expression groups based on median fold change values (0.451 for let-7g, 1.819 for miR-21, and 1.409 for miR-205). Except for a significant association between the low miR-205 expression and ADC histotype (p < 0.0001) compared to SCC, no other statistically significant associations were observed between the analysed miRNAs and the main clinico-pathological characteristics of the NSCLC patients ( Table 1) .
Survival Analysis
To evaluate the relationships of let-7g, miR-21, and miR-205 expression with prognosis of the NSCLC patients, we performed a survival analysis by the Kaplan-Meier method using the disease recurrence and the overall post-operative survival as endpoints. Interestingly, we found that the tumors with a high miR-205 expression showed a significantly shorter mean PFS and OS compared to the patients with a low expression of this miRNA (p = 0.02 and p = 0.03, respectively) (Figure 1) . We did not observe any significant difference in PFS and OS of the NSCLC patients with a high let-7g or miR-21 expression compared to the patients with a low expression of these miRNAs.
Discussion
NSCLC accounts for approximately 70% of all lung cancer-related deaths worldwide [23] , reflecting the need for a better understanding of the mechanisms that underlie lung carcinogenesis. The chance of cure with surgery in early NSCLC is compromised by almost a 30% risk of developing distant metastases, and adjunctive prognostic parameters are necessary to select patients for adjuvant systemic treatments. Previously unknown markers, such as noncoding RNA gene, may also lend insight into the biology of lung cancer. MicroRNAs are a class of short noncoding RNAs that modulate gene expression by targeting messenger RNAs and triggering either the repression of translation or RNA degradation [24] . miRNAs are involved in tissue differentiation during both normal development and carcinogenesis, and miRNA expression profiles have been seen as a promising new class of markers for tumor diagnosis and prognosis [25] [26] [27] . This study was aimed to evaluate let-7g, miR-21, and miR-205 expression profile in early stage NSCLC patients (T1N0), with particular reference to their role in prognosis. In our study, miR-205 evaluation has been shown to have a significant association with SCC histotype, as it has been previously reported [28] . Considering that specific therapies for NSCLC patients are selected depending on the histologic diagnosis, a clinical diagnostic assay based on the expression levels of miR-205 should provide an alternative tool of differential diagnosis, when routinary immunohistochemistry fails. As far as is concerned the clinico-pathological characteristics, we did not observed any significant correlation between the miRNAs expression and the clinico-pathological features, including age, gender, hystotype, tumor grade, smoking habit, and recurrences. In our cases, KaplanMeier survival estimates showed that the early stage NSCLC patients with high miR-205 had a poorer survival than the patients with low expression, either for progression-free survival or overall survival, suggesting that miR-205 could represent a useful marker in the prognostic management of the early-stage (T1N0) NSCLC patients. No difference in the prognosis was found for let-7g and miR-21. Regarding the prognostic role of the analysed miRNAs, Takamizawa et al. [7] first reported low expression of let-7 family members was associated with shorter overall survival in NSCLC; on the contrary, the prognostic role of mature let-7 family members was further investigated, but there were no differences in overall survival between clusters of cases with varying let-7 expression [8] . Similarly, the association between miR-21 or miR-205 expression and NSCLC prognosis has been explored in several studies, but the results are controversial. While some studies showed that miR-21 or miR-205 overexpression was associated with poor NSCLC survival [14] [29] [30] , other studies indicated the converse or insignificant association [31] [32] . To explain discrepancies on the prognostic value of miRNAs in NSCLC, some issues should be addressed. Different kinds of samples are used to detect miRNAs including frozen tissues, formalin-fixed paraffin-embedded (FFPE) tissues, serum and sputum. Saito et al. reported that the results concerning the association of miR-21 expression and NSCLC prognosis from frozen tissues were in apparent contrast to those from FFPE tissues [33] . Therefore, the type of samples could influence the results, and an appropriate sample type should be determined to extract miRNAs. Moreover, published studies have used different cut-point for high vs. low miRNA expression, but a standard cut-off should be identified in order to correctly compare data. In view of these points, further investigations are necessary to have a systematic evaluation of miRNAs in the molecular characterization of the NSCLC patients.
Conclusion
Based on our results, miRNA 205 expression may represent a useful marker in prognostic management of the early-stage (T1N0) NSCLC patients.
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